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SUMMARY 5 
Cytoplasmic dynein-2 is the motor for retrograde intraflagellar transport and mutations in dynein-2 are known to cause 6 
skeletal ciliopathies. Here we define for the first time the composition of the human cytoplasmic dynein-2 complex. We 7 
show that the ciliopathy genes WDR34 and WDR60 are bona fide dynein-2 intermediate chains and are both required 8 
for dynein-2 function. In addition, we identify TCTEX1D2 as a unique dynein-2 light chain that is itself required for cilia 9 
function. We define several subunits common to both dynein-1 and dynein-2 including TCTEX-1 and -3, Roadblock-1 10 
and -3, and LC8-1 and -2 light chains. We also find that NudCD3 associates with dynein-2 as it does with dynein-1. In 11 
contrast, the common dynein-1 regulators dynactin, LIS1, or BICD2 are not found in association with dynein-2. These 12 
data explain why mutations in either WDR34 or WDR60 cause disease as well as identifying TCTEX1D2 as a candidate 13 
ciliopathy gene. 14 
  15 
  16 
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INTRODUCTION 17 
Normal cell function depends on the accurate movement and positioning of intracellular organelles and protein 18 
complexes. Microtubule motor proteins are critical to these processes, with the cytoplasmic dyneins being the primary 19 
minus-end directed microtubule motors. Two cytoplasmic dynein complexes exist in mammalian cells; dynein-1 is the 20 
better characterized of these, being involved in membrane traffic, organelle dynamics and chromosome segregation 21 
during mitosis (Paschal and Vallee, 1987). The cytoplasmic dynein-2 complex on the other hand, mediates the 22 
retrograde component of intraflagellar transport (IFT), the process by which primary and motile cilia as well as flagella 23 
function (Gibbons et al., 1994; Criswell et al., 1996). Retrograde IFT is essential for normal developmental signalling, 24 
notably the Hedgehog pathway in which dynein-2 acts in concert with the IFT-A particle to drive transport of activated 25 
components of this pathway from the cilia tip to the cell body (Huangfu and Anderson, 2005; Liu et al., 2005; May et al., 26 
2005). Furthermore, IFT-A is known to be required for the loading of key components into cilia (Mukhopadhyay et al., 27 
2010; Liem et al., 2012). Defects in the function of primary cilia lead to a cohort of human diseases known as the 28 
ciliopathies (Waters and Beales, 2011); among these, mutations in components of the dynein-2 complex cause Jeune 29 
syndrome, short rib polydactyly type III, and asphyxiating thoracic dystrophy (Dagoneau et al., 2009; Huber et al., 2013; 30 
McInerney-Leo et al., 2013; Schmidts et al., 2013b; Schmidts et al., 2013a).  31 
Dynein-1 is comprised of a dimer of heavy chain subunits (encoded by the DYNC1H1 gene) which associate with two 32 
copies of an intermediate chain (DYNC1I1 or DYNC1I2 depending on the tissue type), two copies of one of two light 33 
intermediate chains (DYNC1LI1 or DYNC1LI2), and a number of light chain subunits (which includes the dynein light 34 
chain (DYNLL1), roadblock (DYNLRB1 and DYNLRB2), and Tctex families (DYNLT1, DYNLT3) (Pfister et al., 2005; 35 
Wickstead and Gull, 2007; Kardon and Vale, 2009)). The light chains are required for the correct assembly of the dynein 36 
complex and have been implicated in controlling its association with cargo molecules. For the majority of its functions, 37 
dynein-1 also associates with one or more binding partners (Kardon and Vale, 2009; Splinter et al., 2012). The best 38 
described of these are the dynactin complex, Lissencephaly-1 protein (LIS1), and bicaudal gene products (notably 39 
BICD2) (Splinter et al., 2012). In contrast, the molecular composition of the dynein-2 complex, notably in mammals, is 40 
not well defined.  41 
Although specific genes encoding a dynein-2-specific heavy (DYNC2H1, also known as DHC1b and DHC2 (Criswell et al., 42 
1996)) and light intermediate chains (DYNC2LI1 also known as LIC3 (Grissom et al., 2002)) have been identified, the full 43 
subunit composition of the motor and biochemical characterization of the subunit composition in metazoans is lacking. 44 
Model organisms such as Chlamydomonas and Tetrahymena have provided further clues that equivalents to the other 45 
known dynein-1 subunits are also present. Chlamydomonas genes encoding FAP133 and FAP163 (orthologues of 46 
mammalian WDR34 and WDR60 respectively) encode functional intermediate chains of algal dynein-2 (Rompolas et al., 47 
2007; Patel-King et al., 2013). FAP133 was shown to have putative LC8 binding motifs and to localize around the basal 48 
body and within the flagellum (Rompolas et al., 2007). Furthermore, LC8 is known to play roles outside of the context of 49 
the dynein-1 complex which could explain some of the FAP133/WDR34 data to date. Our own work has shown that 50 
WDR34 localizes to the pericentrosomal region and is required for ciliogenesis and proper cilia function in vitro (Asante 51 
et al., 2013). We have also previously defined a role for the dynein light chain Tctex-1 in cilia length control, presumably 52 
in association with dynein-2 (Palmer et al., 2011). Others have also shown that WDR34 localizes to a pericentrosomal 53 
region and also that a fluorescent protein fusion of WDR34 (WDR34-tGFP) is present in cilia (Schmidts et al., 2013a). 54 
Furthermore WDR34-tGFP co-immunoprecipitated with FLAG-tagged LC8 consistent with a role for WDR34 in dynein-2 55 
function.  56 
FAP163 has also been shown to localize to the flagellar matrix, to co-purify with FAP133 and LC8, and, in the planarian 57 
Schmidtea mediterranea, to be absolutely required for ciliogenesis (Patel-King et al., 2013). Recent work from several 58 
groups has shown that mutations in the human orthologues of FAP133 (WDR34) and FAP163 (WDR60) cause skeletal 59 
ciliopathies (Huber et al., 2013; McInerney-Leo et al., 2013; Schmidts et al., 2013a). While these data are consistent 60 
with WDR34 and possibly WDR60 being key components of human dynein-2, biochemical data validating this are 61 
lacking. It also remains unclear whether dynein-2 works in cooperation with dynactin or other dynein-1 accessory 62 
complexes. LIS1, for example, is known to function in concert with both cytoplasmic dynein-1 (Faulkner et al., 2000) and 63 
the axonemal dyneins (Pedersen et al., 2007).  64 
3 
 
Since a metazoan dynein-2 complex has not been described in detail, we set out to define the subunit composition of 65 
the human dynein-2 complex and determine whether known dynein-1 regulators also modulate the function of this 66 
poorly characterized second cytoplasmic dynein motor. 67 
  68 
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RESULTS 69 
We generated a human telomerase immortalized retinal pigment epithelial (hTERT-RPE1) cell line stably expressing 70 
WDR34 fused to a monomeric form of GFP (mGFP). Figure 1 shows that mGFP-WDR34 localizes to centrosomes and 71 
primary cilia in serum starved cells as well as showing a diffuse cytoplasmic distribution. This localization to cilia was 72 
confirmed by co-labelling with antibodies directed against acetylated tubulin (Fig. 1A). mGFP-WDR34 also colocalizes at 73 
the base of the cilium with known components of the basal body (γ-tubulin, ODF2, and OFD1, Fig. 1B-D). Fig. 1E shows 74 
that the localization of mGFP-WDR34 within cilia differs from that of the endogenous protein which localizes to 75 
pericentrosomal structures; Fig. 1F shows that the localization of mGFP-WDR34 to cilia is specific as GFP alone is not 76 
localized in cilia.  77 
We sought to use this cell line to define the other proteins associated with WDR34. To achieve this we took a proteomic 78 
approach comparing the interactome of mGFP-WDR34 with mGFP using a GFP-nanotrap (Rothbauer et al., 2006). 79 
Supplementary Table 1 shows the proteomics data for all known dynein-1 and putative dynein-2 components that were 80 
identified in this experiment. Supplementary Table 1A shows the highly efficient isolation of mGFP-WDR34 using this 81 
approach. Large numbers of peptides and spectra were also seen for WDR60 as well as the known dynein-2 heavy chain 82 
(DYNC2H1). We also detected (albeit at low abundance) the known dynein-2 light intermediate chain subunit 83 
DYNC2LI1/LIC3. Listed in Supplementary Table 1B are the dynein light chains that we identified. Here, all known dynein-84 
1 light chain isoforms (LC8-1 and -2, Tctex-1 and -3, and Roadblock-1 and -2) were identified in association with mGFP-85 
WDR34. In addition we detected TCTEX1D2 (also known as Tctex-2). This subunit is not found in association with mGFP 86 
alone. We also noted (Supplementary Table 1C) the association of mGFP-WDR34 with two regulators of dynein-1 87 
function NudC and NudCD3 (also called NudC-like or NUDCL). Supplementary Table 1D then shows the data for the key 88 
dynein accessory factors that were detected in our proteomics. These show that mGFP-WDR34 does not associate with 89 
dynactin, Bicaudal 1, or LIS1 (PAFAH1B) at levels above that of mGFP alone. Bicaudal 2, Spindly, NudE, and Nudel, all of 90 
which are known accessory factors for dynein-1, were not detected at all. We then used these proteomic data to guide 91 
our further biochemical analyses.  92 
The above data indicate that both WDR34 and WDR60 are intermediate chains of the dynein-2 complex. These findings 93 
were then validated using immunoblotting. Fig. 2A shows specific isolation of mGFP-WDR34. Importantly we find that 94 
the endogenous WDR34 does not co-immunoprecipitate with mGFP-WDR34 suggesting that the recombinant form 95 
does not form a complex with the endogenous protein. Immunoblotting for WDR60 showed that this was highly 96 
efficiently isolated in complex with mGFP-WDR34 (Fig. 2B) implying that these two putative intermediate chains might 97 
be present in the same complex. As expected from the proteomic data, the canonical dynein-1 intermediate chain, 98 
IC74, was not immunoprecipitated with mGFP-WDR34 (Fig. 2C) nor was a negative control protein, GAPDH (Fig. 2D). 99 
Two components of the dynactin complex, p150Glued (Fig. 2E) and p50dynamitin (Fig. 2F) also failed to immunoprecipitate 100 
with mGFP-WDR34; similarly, LIS1 was not detected (Fig. 2G). In contrast Tctex-1 (Fig. 2H) and NudCD3 (Fig. 2I) were 101 
both efficiently isolated. Consistent with our identification of TCTEX1D2 in our proteomics, we were able to identify 102 
TCTEX1D2 in association with mGFP-WDR34 (Fig. 2J). TCTEX1D2 is not detectable in whole cell lysates but the 103 
enrichment following GFP-nanotrap isolation of mGFP-WDR34 enables its detection in immunoprecipitates (Fig. 2J). 104 
These data reveal some specificity since both Tctex-1 and NudCD3, but not TCTEX1D2, associate with dynein-1 as 105 
determined in five independent pull downs of dynein-1; dynactin, LIS1, and BICD2 were also always identified in these 106 
dynein-1 pull-downs from both HeLa and RPE-1 cells (unpublished observations). We have been unable to analyze the 107 
dynein-2 heavy chain or light intermediate chain subunits by immunoblotting owing to a lack of available antibodies.  108 
Dynein-2 is predicted to be a large molecular weight complex with a high sedimentation coefficient, similar to 109 
cytoplasmic dynein-1. As predicted for a large macromolecular complex, we found endogenous WDR34 in a large 110 
complex that sedimented on sucrose density gradients in similar fractions to the dynein-1 intermediate chain (Fig. 3A). 111 
This suggests that WDR34 functions in the context of a high molecular weight complex. As expected, mGFP-WDR34 and 112 
WDR60 were both found in large complexes (Fig. 3B and C) consistent with their role as intermediate chains within the 113 
same dynein-2 complex. In contrast, mGFP (Fig. 3B), like the majority of the control protein GAPDH, was found 114 
predominantly in low density fractions as expected. GAPDH is known to associate with many other proteins including 115 
dynein-1 (Zala et al., 2013) which likely explains the low amounts detected across the higher density gradient fractions. 116 
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The expression of mGFP-WDR34 had no significant effect on the distribution of WDR60 across the complex (Fig. 3C). 117 
Some unincorporated mGFP-WDR34 was observed as well as some mGFP itself (Fig. 3C), most likely arising as a result of 118 
proteolytic processing of the recombinant protein at the linker site between mGFP and WDR34. This could also explain 119 
much of the diffuse cytoplasmic labelling seen in Fig. 1. Further to this we undertook gel filtration of cell lysates to 120 
determine the apparent molecular mass of the mGFP-WDR34-containing complexes. Fig. 3D shows that using a 121 
calibrated Superose 6 column, we found that all detectable mGFP-WDR34 fluorescence eluted with the void volume of 122 
the column (Fig. 3D, fraction 15, 7.9 ml) corresponding to high molecular weight components (~1 x 107 Da). GFP by 123 
contrast eluted within the range of 4-7 x 104 Da (Fig. 3D, fractions 33-37). As with the sucrose gradients, it is evident 124 
that there is a significant fraction of mGFP-WDR34 (and also mGFP as a degradation product from this) that elutes in 125 
low molecular weight and low density fractions. This complicates analysis of the exact proportion of mGFP-WDR34 that 126 
is contained within the dynein-2 complex.  127 
We have shown previously that defects in cilia formation and function are evident following depletion of Tctex-1 128 
(Palmer et al., 2011) and WDR34 (Asante et al., 2013) in vitro. Specifically, siRNA-mediated depletion of either of these 129 
genes results in a reduced number of cells that produce cilia but also a lengthening of those cilia that remain. To 130 
determine whether this was true of the newly identified dynein-2 subunits, we first examined the role of WDR60. The 131 
biochemical data shown above suggest that WDR34 and WDR60 might act within the same dynein-2 complex. We 132 
found that endogenous WDR60, like WDR34, also localized around the centrosome (Fig. 4A) and that this localization 133 
was lost following depletion of either WDR60 itself or of WDR34 (Fig. 4A) suggesting that they function together. 134 
Consistent with this, depletion of either WDR34 or WDR60 resulted in a loss of WDR34 labelling around the centrosome 135 
(Fig. 4B). Depletion of WDR60 clearly led to one of two phenotypes, an increase in cilia length (example shown in Fig. 4C 136 
for WDR60 siRNA #1) or a complete loss of an extended axoneme (example shown in Fig. 4C for WDR60 siRNA #2), both 137 
of which were associated with a loss of labelling of WDR60 (Fig. 4C). Quantitation of these data showed that loss of 138 
WDR60 resulted in a significant reduction in the proportion of ciliated cells (Fig. 4D), with a clear increase in length of 139 
the remaining cilia (Figure 4E); this is highly similar to what we observed following depletion of WDR34 (Asante et al, 140 
2013). The increase in cilia length is particularly evident on a cumulative frequency plot (Fig. 4F). Immunoblotting 141 
confirmed the efficacy of WDR34 and WDR60 siRNAs (Fig. 4G) as well as revealing that WDR34 and WDR60 were 142 
reciprocally required for stability of the other. We then repeated our analysis using both WDR34 and WDR60 siRNAs. Of 143 
note, double depletion of both WDR34 and WDR60 did not further exacerbate the cilia phenotypes seen (Fig. 4H, I, and 144 
J). 145 
In our previous work, we showed that the localization of WDR34 to the pericentrosomal region was dependent on the 146 
function of the transmembrane Golgi matrix protein giantin (Asante et al., 2013). If WDR34 and WDR60 are indeed in 147 
complex together then one would predict the same would hold true for WDR60. Fig. 5A shows that loss of giantin 148 
following siRNA depletion does indeed result in a reduction of WDR60 labelling at the centrosome (quantified in Fig. 149 
5B). The degree of loss of giantin also correlated with the intensity of labelling of WDR60 in the pericentrosomal area 150 
(Fig. 5C, quantified in 5D) as we have seen previously for WDR34. The siRNA duplexes used to target giantin have been 151 
characterized previously (Asante et al., 2013) with siRNA #1 being more effective than siRNA #2. This also is evident 152 
from the data seen in Fig. 5D. 153 
We then used similar assays to test the role of NudCD3 in ciliogenesis. We suppressed expression of NudCD3 using 154 
siRNA (Fig. 6A) and found that this diminishes the ability of cells to generate primary cilia (Fig. 6B, quantified in 6C). 155 
Furthermore, those cilia that were seen to remain were found to be longer (Fig. 6D, quantified in 6E with cumulative 156 
frequency plots shown in 6F). Consistent with our other data, depletion of NudCD3 also resulted in a loss of WDR34 157 
around the pericentrosomal region (Fig. 6G, quantified in 6H) without affecting the localization of OFD1 (Fig. 6I) or 158 
pericentrin (Fig. 6B).  159 
We then examined the role of TCTEX1D2 using siRNA transfection. Figure 7A shows the efficacy of three individual 160 
siRNAs measured by quantitative PCR. As shown in Fig. 7B and quantified in Fig. 7C, depletion of TCTEX1D2 results in 161 
longer cilia following serum withdrawal. In all cases we can detect a statistically significant increase in cilia length 162 
following TCTEX1D2 depletion. This is more evident in cumulative frequency plots (Fig. 7D). Notably, the ability of cells 163 
to form primary cilia is not obviously affected following TCTEX1D2 depletion (Fig. 7E).  164 
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DISCUSSION 166 
Here, we provide the first molecular characterization of the human dynein-2 complex. Our data build on previous 167 
reports to provide a comprehensive picture of the subunit composition of this motor as summarized in the schematic in 168 
Figure 8. Our data show that human dynein-2 contains both WDR34 and WDR60 intermediate chain subunits. Individual 169 
cytoplasmic dynein-1 complexes contain two copies of the same intermediate chain and same light intermediate chain 170 
(typically DYNC1I2 in most cells, DYNC1I1 in neurons). Biochemical experiments using Chlamydomonas showed that 171 
FAP133 (WDR34) co-purifies and co-immunoprecipitates with other dynein-2-specific (heavy chain and light 172 
intermediate chain) subunits and with the dynein light chain, LC8. These data are consistent with FAP133 being a 173 
dynein-2 intermediate chain subunit (Rompolas et al., 2007) and led the authors to propose a model in which dynein-2 174 
contains two copies of FAP133, analogous to the dynein-1 complex containing two copies of the intermediate chain. 175 
Our data suggest that in fact dynein-2 contains both WDR34 and WDR60 intermediate chains. This asymmetry has the 176 
potential to provide more functional specialization and greater control of motor function. Furthermore, WDR60 is a 177 
larger protein than either WDR34 or the IC subunits of dynein-1. It is tempting to speculate that this asymmetry is 178 
related to its function. Evidence, primarily from Chlamydomonas, demonstrates that axonemal dyneins contain multiple 179 
intermediate chains within the same complex (Mitchell and Rosenbaum, 1986; King et al., 1991). For example, Inner 180 
arm dynein I1 contains three intermediate chain subunits IC140, IC138, and IC97. Dimeric outer arm dynein from 181 
Chlamydomomas contains two intermediate chain subunits IC1 and IC2. As such cytoplasmic dynein-2 shows similarities 182 
to axonemal dyneins. This could relate to the association of these motors with axonemal microtubules.  183 
It is interesting to note that while mGFP-WDR34 is detectable in cilia, labelling with currently available antibodies does 184 
not detect this pool (also see (Asante et al., 2013; Schmidts et al., 2013a)). These data suggest that the antibody epitope 185 
is occluded within cilia. This could be due to dynein binding to the axonemal microtubules or to other factors such as 186 
the IFT-A particle. The pericentrosomal labelling could indicate a different set of associated factors at the cilia base or 187 
that dynein-2 is assembled at the base of primary cilia exposing a pool of WDR34. We also cannot rule out that WDR34 188 
itself has some function outside of the context of the assembled dynein-2 complex; our gel filtration data are consistent 189 
with the presence of mGFP-WDR34 within or in association with high molecular weight complexes. Our co-190 
immunoprecipitation data argue in favour of all WDR60 being in association with WDR34. Sucrose density gradient 191 
centrifugation shows that there is a proportion of WDR34 outside of the dynein-2 complex that could act in isolation, or 192 
in a heterodimeric complex with WDR60, or in some other complex.  Our gel filtration experiments are also consistent 193 
with this. While we have not been able to monitor the dynein-2 heavy chain by immunoblotting, our previous work with 194 
dynein-1 showed that loss of the intermediate chain subunit did not result in concomitant loss of the heavy chain 195 
(Palmer et al., 2011). These data also therefore do not rule out the possibility of a functional dynein-2 heavy chain 196 
without associated WDR34 and WDR60. However, the importance of these intermediate chain subunits for dynein-2 197 
function is underscored by their conservation through evolution (Wickstead and Gull, 2007). Mutation of either WDR34 198 
(Huber et al., 2013; Schmidts et al., 2013a) or WDR60 (Rompolas et al., 2007) causes skeletal ciliopathies with a similar 199 
phenotype to that seen following mutation of the dynein-2 heavy chain (Dagoneau et al., 2009; Schmidts et al., 2013b). 200 
These findings that WDR34 cannot compensate for loss of function of WDR60 and vice versa are consistent with our 201 
model that both act together in the same dynein-2 complex. We conclude that the full dynein-2 complex including both 202 
WDR34 and WDR60 operates in IFT within cilia.  203 
Analysis of dynein light chain function in the context of cilia biology provides important clues to the way in which 204 
dynein-2 assembles and controls protein distribution within, and retrograde exit from, cilia. The association of Tctex-1 205 
with dynein-2 complexes was predicted from our previous work (Palmer et al., 2011). Here, we now also identify the 206 
TCTEX1D2 light chain (Tctex-2) as a light chain for dynein-2, not present in dynein-1. Tctex-2 has previously been found 207 
to control outer arm dynein assembly in Chlamydomonas flagella (Patel-King et al., 1997; Pazour et al., 1999). Evidence 208 
suggests that, unlike other dynein light chains, TCTEX1D2 is monomeric (DiBella et al., 2001). One possibility is that a 209 
single copy of TCTEX1D2 binds WDR34 with an alternative light chain (or a functionally similar protein) binding to 210 
WDR60. This could diversify the regulation of dynein-2 function and potentially influence the cargo binding capabilities 211 
of the complex. Our data show that a reduction of TCTEX1D2 expression results in an increase in cilia length similar to 212 
that which we observed following depletion of WDR34, WDR60, and giantin. Of note, TCTEX1D2 depleted cells still form 213 
cilia. We cannot reject the idea that TCTEX1D2 is required for cilia formation as these experiments are only depletion 214 
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experiments and not a complete knockout. The moderate phenotype seen here in vitro might also reflect some 215 
functional overlap with other dynein light chains in this system.  It remains unclear whether dynein light chains act in 216 
directing dynein complex assembly and/or in cargo binding. It is also important to note that our in vitro assays reporting 217 
an elongation of cilia do not reflect the situation in vivo where the primary failure appears to be in ciliogenesis i.e. the 218 
formation of the axoneme. Our interpretation is that our siRNA experiments reflect a defect in retrograde IFT.  219 
NudCD3 has been shown to influence the assembly and stability of the dynein-1 complex (Zhou et al., 2006) and 220 
localizes to centrosomes (Cai et al, 2009). Our data are consistent with it playing a similar role with dynein-2. We have 221 
not been able to detect NudCD3 in cilia by immunofluorescence or using epitope tagged forms (Zhou et al., 2006) 222 
arguing in favour of a role in assembly of dynein-2 within the main body of the cell. Association of NudCD3 with both 223 
cytoplasmic dynein complexes makes analysis of its function more complex. Its role in ciliogenesis is most likely linked 224 
to its interaction with dynein-2. However, we would not expect to find mutations in this gene associated with 225 
ciliopathies as a loss-of-function would compromise dynein-1, likely leading to cell death. We also identified the related 226 
NudC protein in our proteomics (Supplementary Table 1C) but as yet we have not investigated further the role of NudC 227 
in cilia or dynein-2 function but we note that NudC has been shown to localize to motile cilia (Pedersen et al., 2007). 228 
In our experiments we typically observe two outcomes following siRNA-mediated suppression of dynein-2 subunits: 229 
fewer cilia but those that remain being longer. We interpret this as a threshold effect of our in vitro experiments. Partial 230 
loss of function compromises retrograde IFT and results in longer cilia (as anterograde IFT continues to deliver 231 
axonemal and other components to the tip). More effective depletion results in an inability of cells to form cilia with 232 
limited or no extension of the axoneme. It is also important to note that longer cilia have not typically been described 233 
for patient mutations, indeed cells from patients with WDR34 mutations show shorter cilia on average (Huber et al., 234 
2013).  However, phenotypic variability, with some cells failing to extend an axoneme while others can, has been seen 235 
in fibroblasts from patients with WDR60 mutations (McInerney-Leo et al., 2013). This distinction between in vitro and in 236 
vivo outcomes necessitates caution in interpretation of data. Nonetheless, our data show clear roles for WDR34, 237 
WDR60, and TCTEX1D2 within the context of the dynein-2 complex.  238 
It is also significant to note that we do not detect any association of dynein-2 with many known regulators of 239 
cytoplasmic dynein-1 and axonemal dynein, including dynactin and LIS1. It is however important to note that while our 240 
work does show that dynactin and LIS1 do not stably associate with dynein-2, our data do not preclude that they do not 241 
associate transiently with dynein-2. For example, LIS1 acts in the initiation of dynein-1 motility but does not remain 242 
associated with it during organelle transport (Egan et al., 2012). Consistent with such a model, although we do not 243 
detect LIS1 in association with dynein-2 by co-immunoprecipitation, we can localize LIS1 to primary cilia by 244 
immunofluorescence (unpublished observations). LIS1 is also believed to act in generating a persistent force state of 245 
dynein to aid its function in moving heavy loads (McInerney-Leo et al., 2013). While such functions are required of 246 
dynein-1 (for example in nuclear migration) and axonemal dyneins (in generating the force of cilia and flagellar beating) 247 
it is conceivable that such large cargo loads are not part of the cargo repertoire transported by dynein-2. LIS1, dynactin 248 
and BICD family proteins likely cooperate to direct association of dynein with cargo and subsequent motility (Egan et al., 249 
2012; Splinter et al., 2012; Wang et al., 2013; Moon et al., 2014). The absence of dynactin suggests that other as yet 250 
unidentified accessory factors likely act in cooperation with dynein-2 in linking the motor to its cargo. Other recent in 251 
vitro reconstitution experiments have shown that dynein-1 requires the association of both dynactin and another 252 
accessory factor such as BICD2 to induce a processive state (McKenney et al., 2014; Schlager et al., 2014). Dynein-2 is 253 
also likely to be a processive motor and it is tempting to speculate that additional factors are required to induce 254 
processivity, possibly the IFT-A complex itself. Further biochemical and biophysical analysis would undoubtedly help to 255 
address such questions.  256 
In conclusion, our characterization of the subunit composition of cytoplasmic dynein-2 defines a requirement for both 257 
WDR34 and WDR60 in dynein-2 function, explaining why mutations in either gene cause disease. Furthermore, this 258 
work identifies TCTEX1D2 as a candidate ciliopathy gene. 259 
   260 
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MATERIALS AND METHODS 261 
All reagents were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated.  262 
GROWTH OF CULTURE CELLS 263 
Human telomerase immortalized retinal pigment epithelial cells (hTERT-RPE1) were maintained in DMEM-F12 264 
supplemented with 10% FCS (Life Technologies, Paisley, UK) containing supplemented 1% L-glutamine and 1% essential 265 
amino-acids. Cells were seeded onto 35 mm glass bottom dishes (MatTek, Ashland, MA). 266 
CILIOGENESIS ASSAY  267 
On reaching confluence, hTERT-RPE1 cells were rid of serum by washing twice with PBS and incubated at 37 °C/5% CO2 268 
for 24–48 h in serum-free medium to induce cell cycle exit and subsequent cilium assembly. Cells were fixed and 269 
typically labelled with anti-acetylated tubulin to mark primary cilia. Cilia lengths were measured using the Fiji 270 
implementation of Image J (Schindelin et al, 2012).  271 
SOURCE OF ANTIBODIES  272 
Antibodies used include: rabbit polyclonal anti-WDR60 (HPA020607), rabbit polyclonal anti-NudCD3 (HPA019136), 273 
rabbit polyclonal anti-ODF2 (HPA001874), mouse monoclonal anti-acetylated tubulin (T6793) and mouse monoclonal 274 
anti-γ-tubulin (T6557) (all from Sigma-Aldrich); rabbit polyclonal anti-giantin (PRB-114C), mouse monoclonal anti-GFP 275 
(MMS-118P) and rabbit polyclonal anti-pericentrin (PRB-432C) (all from Covance, CA); mouse monoclonal anti-276 
p150glued (610473) and mouse monoclonal anti-p50dynamitin (BD 611003) (both from BD Biosciences, Oxford, UK); 277 
rabbit polyclonal anti-WDR34 (NBP1-88805, Novus Biologicals, Cambridge, UK), rabbit polyclonal anti-Tctex1 (sc-28537, 278 
Santa Cruz Biotechnology, Dallas, TX), mouse monoclonal anti-GAPDH (ab9484, Abcam, Cambridge, UK), rabbit 279 
polyclonal anti-TCTEX1D2 (ab139804, Abcam), mouse monoclonal anti-DIC74 (MAB1618, Millipore, Feltham, UK), rabbit 280 
polyclonal anti-Lamin A/C (2032, Cell Signaling Technologies, Hitchin UK), rabbit polyclonal anti-OFD1 (a generous gift 281 
from Andrew Fry, University of Leicester, UK), and rabbit polyclonal anti-LIS1 (A300-409A, Bethyl Laboratories, from 282 
Cambridge Bioscience, Cambridge, UK). Cy2-conjugated donkey anti-mouse (715-225-151), Cy3-conjugated donkey 283 
anti-rabbit (711-165-152), peroxidase-conjugated donkey anti-mouse IgG (715-035-150) and peroxidase-conjugated 284 
donkey anti-rabbit IgG (711-035-150) were supplied by Jackson ImmunoResearch (from Stratech Scientific, Newmarket, 285 
UK). IRDye 800CW donkey anti-mouse (926-32212) and IRDye 680 donkey anti-rabbit (926-32223) were from Li-Cor 286 
(Cambridge, UK). 287 
CLONING OF MGFP-WDR34, GENERATION OF LENTIVIRUSES AND STABLE CELL LINES 288 
The human WDR34 gene (RefSeq: NM_052844.3) was amplified from the Origene cDNA (SC319901, Cambridge 289 
Bioscience) by PCR using Phusion™ high-fidelity DNA polymerase PCR kit (New England BioLabs, Hitchin, UK) with 290 
forward primer (5’-GGAA-CTCGAG-ATGGCAACCCGCGCGCAGCC-3’) and reverse primer (3’-GAAA-GAATTC-291 
TCAGGCCGCCACCTCTGCTGC-5’), containing the XhoI and EcoRI restriction sites, respectively. The PCR product was sub-292 
cloned into a modified pLVX-Puro vector (Clontech, Mountain View, CA) that includes the mGFP sequence flanked by 293 
XhoI and EcoRI restriction sites. The resultant pLVX-Puro-mGFP-WDR34 CDNA was amplified in XL10-Gold 294 
ultracompetent bacterial cells (Stratagene) and harvested from the bacterial cells using QIAprep Spin Miniprep Kit 295 
(Qiagen, Manchester, UK). All plasmid minipreps were validated by restriction analysis and subsequently sequenced to 296 
facilitate secondary validation by sequence alignment analysis.  297 
Lentiviral particles of pLVX-Puro-mGFP-WDR34 were produced in HEK293T cells using the Lenti-X™ HTX Packaging 298 
System (Clontech), and low passage hTERT-RPE1 cells transduced with the resultant viral supernatant, strictly according 299 
to manufacturer’s directives. 48 h post-transduction, confluent cells were subcultured into 10 % FBS supplemented 300 
DMEM F-12 HAM (Sigma-Aldrich, Poole, UK) containing 5 µg/ml puromycin. Cells were maintained in 0.25 µg/ml 301 
puromycin after this. 302 
PROTEOMICS  303 
3 x 15 cm dishes each of hTERT-RPE1-mGFP (control) and hTERT-RPE1-mGFP-WDR34 cells were serum-starved for 24 h 304 
at confluence to induce ciliogenesis. Cells were briefly washed twice with 20 mL ice-cold PBS per dish and PBS drained 305 
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off completely by leaning the dishes at ~60o for ~10 s. 500 µL of ice-cold lysis buffer 1 (10 mM Tris-HCl [pH=7.4], 50 mM 306 
NaCl, 0.5 mM EDTA, 1.0 % Igepal [CA-630, Sigma], containing freshly added 1mM phenylmethane sulfonylfluoride 307 
[PMSF] and 1x EDTA-free Protease Inhibitor Cocktail Set V [539137, Millipore, UK]) was added to the cells and the cells 308 
scraped off the dish floor into 2 mL tubes. Cells were lysed by incubation with the buffer on a rotor at 4 oC/30 min. 309 
Lysates were centrifuged at 20,000 g/4 oC/10 min and supernatants transferred into pre-cooled 2 mL eppendorf tubes.  310 
EQUILIBRATION OF GFP NANO-TRAP BEADS AND IMMUNOPRECIPITATION 311 
20 µL of resuspended GFP nano-trap beads (Chromotek, Planegg-Martinsried, Germany) per sample was added to ice-312 
cold 500 µL dilution buffer (10 mM Tris-HCl [pH=7.4], 50 mM NaCl, 0.5 mM EDTA, freshly added 1 mM PMSF and 1x 313 
EDTA-free Protease Inhibitor Cocktail), spun down at 2700 g/2 min/4 oC and the supernatant discarded. This wash was 314 
repeated 2 additional times. The cell lysate supernatants were added to the equilibrated beads and incubated on a 315 
rotor 4 oC/2 h.  316 
SAMPLE PREPARATION FOR MASS SPECTROMETRY 317 
At the end of the incubation the tubes were centrifuged at 2000 g/2 min/4 oC and the supernatants discarded. 500 µL 318 
of ice-cold dilution buffer was added to the protein-bound beads (pellets), the tubes inverted gently ~10 times to 319 
resuspend contents and spun down at 2000 g/2 min/4 oC. This wash was repeated 2 more times after which the beads 320 
were resuspended in 50 µL 2X lithium dodecyl sulphate (LDS) sample buffer (NP0007, Life Technologies Ltd, Paisley, UK) 321 
(106 mM Tris-HCl, 141 mM Tris-base, 2 % LDS, 10 % Glycerol, 0.51 mM EDTA, 0.22 mM SERVA® Blue G250, 0.175 mM 322 
Phenol Red [pH 8.5]) containing 1x Nupage® sample reducing agent (500 mM dithiothreitol) (NP0004). The beads were 323 
boiled at 95 oC/10 min to denature proteins and dissociate precipitated proteins from the GFP nano-trap beads and the 324 
tubes immediately placed on ice for 1 min to condense vaporised contents. The tubes were centrifuged at 325 
2700 g/2 min/4 oC, to sediment beads and the supernatants collected into fresh 1.5 mL eppendorf tubes. These 326 
samples were submitted to the University of Bristol’s proteomics facility for mass spectrometry analysis. 327 
MASS SPECTROMETRY 328 
Samples were run on a 10 % acrylamide gel to separate proteins. Each gel lane was cut into 6 slices and each slice put 329 
through in-gel tryptic digestion in a ProGest automated digestion unit (Digilab UK). An Ultimate 3000 nano HPLC system 330 
operated in line with an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific) was employed in fractionating the 331 
resulting peptides. Summarily, peptides in 1% (vol/vol) formic acid were injected onto an Acclaim PepMap C18 nano-332 
trap column (Thermo Scientific). The peptides were washed with 0.5 % (vol/vol) acetonitrile in 0.1 % (vol/vol) formic 333 
acid and resolved on a 250 mm × 75 μm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over 334 
a 150 min organic gradient composed of 7 gradient segments. Peptides were run over the column through the 335 
following sequential gradients: 1-6 % solvent B/1 min (solvent B = aqueous 80 % acetonitrile in 0.1 % formic acid; 336 
solvent A = 0.1 % formic acid), 6-15 % B/58 min, 15-32 % B/58 min, 32-40 % B/5 min, 40-90 % B/1 min, 90 % B/6 min 337 
and finally, 1 % B/1 min; with a flow rate of 300 nL/min. Peptides were subjected to 2.1 kV nano-eloctrospray ionisation 338 
from a 30 µm (internal diameter) stainless steel emitter (Thermo Scientific) with a capillary temperature of 250 oC. An 339 
LTQ-Orbitrap Velos mass spectrometer operated by the Xcalibur 2.1 software (Thermo Scientific) in data-dependent 340 
acquisition mode was used to acquire tandem mass spectra of the peptides. Survey scans were analysed at 60,000 341 
resolution (at m/z 400) within the mass range m/z 300-2000, and the top 20 multiple-charged ions in each duty cycle 342 
selected for MS/MS in the LTQ linear ion trap. Charge state filtering, which excludes unassigned precursor ions from 343 
fragmentation, and dynamic exclusion (repeat count, 1; repeat duration, 30 s; exclusion list size, 500) were applied. The 344 
following fragmentation conditions were set in the LTQ: 40 % normalised energy of collision, 0.25 activation q, 10 ms 345 
activation time, and a minimum ion selection intensity of 500 counts. 346 
Proteome Discoverer software (version 1.2, Thermo Scientific) was used to process and quantify the raw data files, 347 
which were then searched against the UniProt human database (122604 sequences) using the SEQUEST algorithm 348 
(version 28, revision 13). Tolerances of 10 ppm and 0.8 Da were set for peptide precursor mass and MS/MS, 349 
respectively. Cysteine carbamidomethylation (+57.0214) and methionine oxidation were included in the search criteria 350 
as fixed modifications and variable modifications, respectively. Searches were performed with full tryptic digestion 351 
allowing a maximum of 1 missed cleavage. All peptide data was filtered to satisfy a 5 % false discovery rate (FDR) by 352 
enabling the reverse database search option. The Proteome Discoverer software creates a reverse “decoy” database 353 
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from the same protein database; peptides evading the initial filtering parameters that were derived from this decoy 354 
database are badged as false positive identifications. The minimum cross-correlation factor (Xcorr) filter was separately 355 
readjusted for each individual charge state to meet the predetermined target 5 % FDR, considering the number of 356 
random false positive matches from the reverse decoy database. Those proteins identified in Supplementary Table 1 357 
were selected on the basis of being known components or well-characterized interactors of cytosplasmic dynein-1.  358 
GFP-TRAP IMMUNOPRECIPITATION 359 
Cells were grown to confluence in 15 cm dishes and serum starved for 24 h. Cells were washed twice with ice-cold PBS, 360 
lysed with 500 µl ice-cold buffer (10 mM Tris-HCl pH=7.4, 50 mM NaCl, 0.5 mM EDTA, 1.0% Igepal CA-630, 1 mM PMSF 361 
and 1x Protease inhibitor cocktail) on rotator for 30 mins/4 oC and lysate supernatant collected after centrifuging at 362 
20,000 g/10 mins/4 oC. Lysate supernatants were incubated with equilibrated GFP nano-trap beads (Chromotek) on 363 
rotator for 90 mins/4 oC after which the beads were washed three times with 500 µl dilution buffer (10 mM Tris-HCl 364 
pH=7.4, 50 mM NaCl, 0.5 mM EDTA, 1 mM PMSF and 1x Protease inhibitor cocktail) by centrifuging at 365 
2000 g/2 mins/4 oC. Beads were resuspended in 50 µl 2x LDS sample buffer (Life Technologies) containing sample 366 
reducing agent (Life Technologies) and boiled at 95 oC/10 mins, followed by SDS-PAGE and immunoblotting as 367 
described below. 368 
SMALL INTERFERING RNA TRANSFECTION  369 
Cells were siRNA-transfected by calcium phosphate method at 3% CO2 (Chen & Okayama, 1988). The medium was 370 
changed 20 hours post-transfection and cells were washed with PBS and were incubated for 72 hours (at 37°C and 5% 371 
CO2) with fresh supplemented media. SiRNA duplexes were designed using online algorithms of, and subsequently 372 
synthesized by, MWG-Eurofins. BLAST search was performed for these duplexes against the non-redundant database to 373 
determine their specificity. Lamin A/C or luciferase GL2 were depleted as targeted controls.  374 
Sequences used were as follows:  375 
Giantin was depleted with giantin siRNA (#1) ACUUCAUGCGAAGGCCAAATT and giantin siRNA (#2) 376 
AGAGAGGCUUAUGAAUCAATT. Duplexes for suppressing WDR34 were (#1) GAUGGUGUCUUGUCUGUAU and (#2) 377 
GCUGUUUGAUCUCCAGAAA. WDR60 was targeted with (#1) CCAUUUGGAGAACCAAUAU and (#2) 378 
CAUGGUAUAAGACCAGUGA. Duplexes targeting NUDCD3 include (#1) GUGAUGCAGUGGUGUGAGA and (#2) 379 
GAGAAGGCAGGAACUUGAA. Luciferase GL2 (CGUACGCGGAAUACUUCGAUU) and lamin A/C 380 
(CUGGACUUCCAGAAGAACA) were used as targeted negative and positive controls, respectively. All siRNAs were 381 
purchased from MWG Eurofins (Ebersberg, Germany). TCTEX1D2 was depleted with (#1) 382 
AGAGGUGAAGGAGUAUUCATT, (#2) UGCUGAAUAUUCUCCAGAATT and (#3, targeting 3’UTR) 383 
AGGACAUGACCAUGAAGAATT 384 
QUANTITATIVE PCR 385 
RNA was extracted from transfected cells using a Qiagen RNeasy purification kit according to the manufacturer’s 386 
instructions (Qiagen, Manchester, UK) . cDNA was generated using an SuperScriptTM III First Strand Synthesis System 387 
(Life Technologies). DNA was amplified under the following conditions: 95oC for 10 minutes then 30 cycles of 95oC for 388 
30 seconds, 55oC for 30 seconds, 70oC for 15 seconds. Amplification was monitored by incorporation of SYBR® Green 389 
(Finnzyme, Espoo, Finland) and analysed on a BioRad Opticon 2 PCR system (BioRad, Hemel Hempstead, UK). Gene 390 
expression was quantified by the ∆∆CT method (Livak & Schmittgen, 2001) normalizing against GAPDH. Single product 391 
amplification was verified by performing melting curve analysis and gel electrophoresis. Primers (MWG Eurofins) used 392 
were as follows: TCTEX1D2 forward primer: 5’- GGAGCCCGAGAACACCTATATT-3’; reverse primer: 5’- 393 
GCTGAGGCATTTCTTCTGGAGA-’; GAPDH forward primer: 5’-ATCCCATCACCATCTTCCAG-3’; reverse primer: 5’- 394 
CCATCACGCCACAGTTTCC-3’. 395 
SUCROSE DENSITY GRADIENT CENTRIFUGATION 396 
Cells were grown and lysed as described for the GFP-trap experiment and lysate supernatants layered onto 5-40% or 5-397 
20% continuous sucrose gradient columns. The former were poured using a Perspex gradient mixer, the latter using 398 
Biocomp isopycnic gradient forming tube caps (10 mm isopycnic long caps, Biocomp from Wolf Laboratories, 399 
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Manchester, UK). Gradients were centrifuged at 23,700 rpm (96119 xg)/18 h/4 oC in a TH-641 swinging bucket rotor 400 
(Thermo Scientific). Proteins were precipitated with 250 µl or 125µl 100% trichloroacetic acid at 4 oC /1 h from 1 ml or 401 
500 μl column fractions respectively, pelleted by centrifuging at 13,200 rpm/5 mins/4 oC, and washed three times with 402 
150 µl ice-cold acetone. The acetone was chased off by incubation at room temperature for 30 minutes and pellets 403 
resuspended in 1x LDS sample buffer containing reducing agent.  404 
IMMUNOBLOTTING 405 
For immunoblots to validate siRNA efficacy, cells were lysed and samples were separated by SDS-PAGE followed by 406 
transfer to nitrocellulose membranes; primary antibodies were detected using HRP-conjugated secondary antibodies 407 
(Jackson ImmunoResearch, West Grove, PA) and enhanced chemiluminescence (ECL, GE Healthcare, Cardiff, United 408 
Kingdom). Immunoblots in Fig. 6 were developed using an Odyssey Sa imager (Li-Cor, Cambridge, UK).  409 
GEL FILTRATION  410 
The following buffer was used for gel filtration: 30 mM HEPES (pH 7.0), 150 mM KOAc, 2 mM MgSO4, 0.68 M glycerol, 2 411 
mM DTT. A 24 ml Superose 6 column (GE Healthcare) was calibrated using 70S ribosome, apoferritin, b-amylase, bovine 412 
serum albumin and carbonic anhydrase. Cells expressing either GFP or mGFP-WDR34 were lysed at 4oC using a ball 413 
bearing cell homogenizer with 10 µm clearance (Isobiotec, Heidelberg) in gel filtration buffer and cleared by 414 
centrifugation for 30 minutes at 25,000 xg. Fractions (0.5ml each) were collected and fluorescence of each sample 415 
measured using a Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies, Santa Clara, CA) at 25oC with 416 
excitation at 490 nm (5 nm excitation slit) and emission scanning 500-600 nm with 5 nm emission slits.  417 
IMMUNOLABELLING AND MICROSCOPY  418 
Medium was removed and cells were subsequently washed with PBS. Cells were then fixed using cold methanol for 4 419 
minutes at -20oC. For images in Figure 1E and 1F, cells were fixed with 4% paraformaldehyde in PBS, permeabilized with 420 
0.1% Triton X-100 for 5 minutes and then washed in PBS. After two washes in PBS, cells were blocked using a 3% bovine 421 
serum albumin (BSA) in PBS for 30 minutes at room temperature. Three washes with PBS of 5 minutes each at room 422 
temperature were done after each of the primary and secondary antibody incubations. Nuclear staining was done using 423 
DAPI (4,6-Diamidino-2-phenylindole (Life Technologies) diluted at 1:5000 in distilled water) for 3 minutes at room 424 
temperature, cells were then rinsed twice in PBS. Cells were imaged using an Olympus IX-71 or IX-81 widefield 425 
microscope with a 63x 1.42 N.A. objective, and excitation and emission filter sets (Semrock, Rochester, NY) controlled 426 
by Volocity software (v. 4.3, Perkin-Elmer, Seer Green, UK).  427 
PROCESSING AND QUANTIFICATION OF IMAGE DATA AND STATISTICAL ANALYSIS 428 
Representative images are shown, all experiments were repeated independently at least three times each. Samples 429 
were compared using Kuskall-Wallis one-way analysis of variance with Dunn’s post-hoc test using GraphPad Prism v 4. 430 
All images were prepared with Adobe Photoshop and Adobe Illustrator. All data and resulting statistical analyses arise 431 
from 3 independent experiments. 432 
  433 
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FIGURE LEGENDS 447 
Figure 1: Localization of mGFP-WDR34. (A) mGFP-WDR34 (green) localizes to a cytosolic pool and to primary cilia 448 
colocalizing with acetylated tubulin (red). (B) γ-tubulin labelling, (C) ODF2, and (D) OFD1 (red in each case) demonstrate 449 
the accumulation of mGFP-WDR34 at the base of the cilium with some labelling evident along its length. (E) Cells 450 
expressing mGFP-WDR34 were fixed with paraformaldehyde and labelled to detect acetylated tubulin and WDR34 as 451 
indicated. Two examples are shown. (F) Cells expressing GFP were processed as in (E) to demonstrate an absence of 452 
GFP from primary cilia. Bars (all panels) = 5 μm. 453 
Figure 2: Immunoprecipitation from serum-starved RPE1 cells stably expressing either mGFP or mGFP-WDR34. GFP-454 
traps of cells expressing mGFP alone or mGFP-WDR34 were separated by SDS-PAGE and immunoblotted to detect (A) 455 
WDR34, (B) WDR60, (C) IC74 (DYNC1I2), (D) GAPDH, (E) p150Glued, (F) p50dynamitin, (G) LIS1, (H) Tctex-1, (I) NudCD3, or (J) 456 
TCTEX1D2 as indicated. Molecular weight markers are shown (kDa). In each case the lanes show I = input, U = unbound 457 
fraction, B = bound fraction as indicated.  458 
Figure 3: Sucrose density gradient centrifugation of cell lysates from RPE1 cells. (A) RPE1 cells were lysed and loaded 459 
onto a 5-40% sucrose density gradient. After centrifugation, 1 ml fractions were removed from the gradient and probed 460 
by immunoblotting to determine the distribution across the gradient of DIC74 (DYNC1I2), WDR34, or GAPDH. (B) RPE1 461 
cells stably expressing (B) GFP or (C) mGFP-WDR34 were lysed and loaded onto a 5-20% sucrose density gradient. 462 
Twenty 500 µl fractions were collected post-centrifugation and alternate fractions analysed by SDS PAGE and 463 
immunoblotting for GFP, DIC74, GAPDH and WDR60. (D) Gel filtration of lysates from GFP expressing cells (gray bars) 464 
and mGFP-WDR34 expressing cells (black bars). Molecular mass calibration is shown below the graph aligned to the 465 
fraction numbers.  466 
Figure 4: The stabilities of WDR34 and WDR60 are interdependent. (A, B) Cells were transfected with siRNA duplexes 467 
targeting WDR34 or WDR60 as indicated and following serum starvation, fixed and immunolabelled to detect acetylated 468 
tubulin and (A) WDR60 or (B) WDR34. (C) Cells depleted of WDR60 were effectively depleted (shown by loss of 469 
immunoreactivity around the centrosome) and labelling showed either longer cilia (example shown for WDR60-1) or a 470 
failure to generate cilia (example shown for WDR60-2). (D) Quantitation of the proportion of cells that produced cilia in 471 
response to 24 hours serum starvation. Asterisks indicate statistical significance (* p<0.05; ** p<0.01). (E) Lengths of 472 
remaining cilia were measured for control (GL2) or WDR60-depleted cell cultures. Bars show mean and s.d.; asterisks 473 
indicate statistical significance (*** p<0.001). (F) Distribution of cilium length represented as a cumulative frequency 474 
chart of the percentage of total cilia found in 0.25 µm bins. Data plotted is the same as in (E). (G) Immunoblotting 475 
confirmed the efficacy of WDR34 and WDR60 siRNAs. Immunoblotting for WDR34 following suppression of WDR60 and 476 
vice versa was also used to test interdependency of these subunits. Lamin A/C is included as a negative control, GAPDH 477 
as a loading control. Molecular weight markers are indicated (kDa). (H, I) Results were analysed to determine whether 478 
depletion of both WDR34 and WDR60 simultaneously could enhance the phenotypes seen in terms of (H) the number 479 
of cells producing cilia or (I) the length of remaining cilia. In both cases no additive effect is seen. Bars show mean and 480 
s.d.; asterisks indicate statistical significance (*** p<0.001). (J) Distribution of cilium length represented as a cumulative 481 
frequency chart of the percentage of total cilia found in 0.25 µm bins. Data plotted is the same as in (I). Bar (all panels) 482 
= 10 μm. 483 
Figure 5: Suppression of giantin results in a loss of pericentrosomal WDR60. (A) Cells depleted of giantin were labelled 484 
to detect acetylated tubulin and WDR60. (B) The area of pericentrosomal WDR60 labelling was measured and plotted 485 
(arbitrary units; bars indicate mean and s.d.; asterisks indicate statistical significance: *** p<0.001). (C) The loss of 486 
pericentrosomal WDR60 labelling correlates with the efficacy of giantin suppression. (D) Data were quantified and the 487 
correlation tested using both Pearson’s and Spearman coefficients. Colour coding indicates siRNA transfection as 488 
indicated. Bar (all panels) = 10 μm. 489 
Figure 6: NudCD3 is required for ciliogenesis and cilia length control. Two independent siRNA duplexes targeting 490 
NudCD3 were used. (A) Immunoblots show tubulin as a loading control, lamin A/C as a siRNA control and NudCD3. (B) 491 
Cells were immunolabelled to detect pericentrin and acetylated tubulin. Enlargements highlight the failure to extend 492 
cilia from the basal body in NudCD3-depleted cells. (C) The proportion of ciliated cells was quantified; asterisks indicate 493 
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statistical significance (* p<0.05). (D) Further examples of NudCD3 depleted cells show those in which cilia are evident. 494 
(E) Quantitation shows that in cells depleted of NudCD3 that extended cilia, these were longer than those seen in 495 
control cells. Bars show mean and s.d.; asterisks indicate statistical significance (*** p<0.001). (F) Distribution of cilium 496 
length represented as a cumulative frequency chart of the percentage of total cilia found in 0.25 µm bins. Data plotted 497 
is the same as in (E). (G) Depletion of NudCD3 results in a loss of pericentrosomal WDR34 (red) as shown by 498 
immunofluorescence. The centrosome and cilia are labelled with acetylated tubulin. (H) Data were quantified and 499 
statistical significance is indicated, ** = p<0.05, *** = p<0.01. (I) Suppression of NudCD3 does not affect the 500 
accumulation of OFD1 (red) around the centrosome (acetylated tubulin, green). Bar (all panels) = 10 μm.  501 
Figure 7: TCTEX1D2 depletion increases cilia length. RPE1 cells were depleted of TCTEX1D2 using 3 different siRNA 502 
duplexes as indicated and then serum starved for 24 hours prior to (A) analysis by QPCR or (B-D) fixation and 503 
immunolabelling to detect acetylated tubulin and pericentrin. (A) Relative TCTEX1D2 mRNA expression in transfected 504 
cells, as determined by RT-PCR. Error bars show s.e.m. (n=3). (B) Representative maximum intensity z-stack projections 505 
of control and depleted cells. Enlargements highlight the increase in cilia length upon TCTEX1D2 depletion. Bar = 10 µm. 506 
(C) Dot plot comparing cilia lengths in control and TCTEX1D2 depleted cells. Bars show mean and s.d. (p<0.001, n=3). 507 
(D) Distribution of cilium length represented as a cumulative frequency chart of the percentage of total cilia found in 508 
0.25 µm bins. Data plotted is the same as in (B). (D) The percentage of ciliated cells found in control and TCTEX1D2 509 
depleted cells. There is no consistent change following siRNA treatment. Error bars show s.e.m.  510 
Figure 8: Schematic of cytoplasmic dynein-1 and dynein-2 complexes. Light intermediate chains are shown as hexagons, 511 
intermediate chains as extended ovals, and light chains as circles. Additional interacting partners are seen for dynein-1 512 
(left) that are not associated with dynein-2 (right). NudCD3 associates with both cytoplasmic dynein complexes. It 513 
remains unclear whether TCTEX1D2 is present as a monomer or dimer within the complex.  514 
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TABLE 1: PROTEOMIC ANALYSIS OF MGFP-WDR34 VERSUS MGFP IN STABLY-TRANSFECTED, SERUM-STARVED HTERT-RPE1 CELLS.  
TABLE 1A: CYTOPLASMIC DYNEIN-2 SUBUNITS, NOT FOUND ASSOCIATED WITH DYNEIN-1 
Accession # AAs 
MW 
[kDa] Description 
Score 
mGFP 
Coverage 
mGFP 
# 
PSM 
mGFP 
# 
Peptides 
mGFP 
Score 
mGFP-
WDR34 
Coverage 
mGFP-
WDR34 
# PSM 
mGFP-
WDR34 
# Peptides  
mGFP-
WDR34 Annotation 
Q96EX3 536 57.8 WD repeat-
containing protein 
34 GN=WDR34 
137.93  44.59 31 16 3732.64  79.85 873 34 
DYNEIN WDR34 
Q8WVS4 1066 122.5 WD repeat-
containing protein 
60 GN=WDR60 
n.d. n.d. n.d. n.d. 329.54  37.24 89 33 
DYNEIN WDR60 
B0I1S0 4307 492.3 DYNC2H1 variant 
protein 
GN=DYNC2H1  
n.d. n.d. n.d. n.d. 37.31  2.48 10 10 
DYNEIN HEAVY 
CHAIN 2 
E5RJK4 72 7.9 Cytoplasmic 
dynein-2 light 
intermediate chain 
GN=DYNC2LI1  
n.d. n.d. n.d. n.d. 5.38  20.83 1 1 
DYNEIN LIC3 
Q8WW35 142 16.1 Tctex1 domain-
containing protein 
2 GN=TCTEX1D2  
n.d. n.d. n.d. n.d. 110.43  45.07 24 5 
DYNEIN 
TCTEX1D2 
n.d. =  not detected 
  
TABLE 1B: DYNEIN-1 LIGHT CHAINS ALSO FOUND ASSOCIATED WITH DYNEIN-2 
Accession 
# 
AAs 
MW 
[kDa] Description 
Score 
mGFP 
Coverage 
mGFP 
# 
PSM 
mGFP 
# 
Peptides 
mGFP 
Score 
mGFP-
WDR34 
Coverage 
mGFP-
WDR34 
# PSM 
mGFP-
WDR34 
# Peptides  
mGFP-
WDR34 Annotation 
P63172 113 12.4 Dynein light chain 
Tctex-type 1  
GN=DYNLT1 
n.d.   n.d. n.d.  n.d.  84.63  60.18 19 4 
DYNEIN 
TCTEX1 
P51808 116 13.1 Dynein light chain 
Tctex-type 3 
GN=DYNLT3  
n.d.   n.d. n.d.  n.d.  7.97  23.28 3 2 
DYNEIN 
TCTEX3 
A4D1D1 297 32.5 Similar to dynein, 
cytoplasmic, light 
peptide; 8kD LC; 
dynein LC8; 
protein inhibitor of 
neuronal nitric 
oxide synthase 
GN=LOC392067 
n.d.  n.d.  n.d.  n.d.  4.21  7.41 2 1 
DYNEIN LC8 
P63167 89 10.4 Dynein light chain 
1, cytoplasmic 
OS=Homo sapiens 
GN=DYNLL1  
23.71  64.04 7 5 405.41  64.04 109 6 
DYNEIN LIGHT 
CHAIN 1 
Q96FJ2 89 10.3 Dynein light chain 
2, cytoplasmic 
OS=Homo sapiens 
GN=DYNLL2  
19.29  25.84 5 3 255.84  65.17 81 6 
DYNEIN LIGHT 
CHAIN 2 
Q9NP97 96 10.9 Dynein light chain 
roadblock-type 1 
OS=Homo sapiens 
GN=DYNLRB1  
52.23  55.21 16 4 709.81  85.42 202 10 
DYNEIN 
ROADBLOCK 
Q8TF09 96 10.8 Dynein light chain 
roadblock-type 2 
OS=Homo sapiens 
GN=DYNLRB2  
19.08  16.67 6 2 170.55  33.33 54 3 
DYNEIN 
ROADBLOCK 2 
n.d. =  not detected 
  
TABLE 1C: DYNEIN-1 ACCESSORY FACTORS ALSO FOUND IN ASSOCIATION WITH DYNEIN-2 
Accession 
# 
AAs 
MW 
[kDa] Description 
Score 
mGFP 
Coverage 
mGFP 
# 
PSM 
mGFP 
# 
Peptides 
mGFP 
Score 
mGFP-
WDR34 
Coverage 
mGFP-
WDR34 
# PSM 
mGFP-
WDR34 
# Peptides  
mGFP-
WDR34 Annotation 
B0FTY2 361 40.8 NudC-like protein 
OS=Homo sapiens 
GN=NUDCD3  
n.d.  n.d.  n.d.  n.d.  7.77  5.54 3 2 
NUDCD3 
Q9Y266 331 38.2 Nuclear migration 
protein NudC 
OS=Homo sapiens 
GN=NUDC  
7.33  3.32 2 1 27.18  10.57 7 3 
NUDC 
n.d. =  not detected 
 
TABLE 1D: DYNEIN-1 ACCESSORY FACTORS THAT WERE NOT FOUND IN ASSOCIATION WITH DYNEIN-2 
Accession 
# 
AAs 
MW 
[kDa] Description 
Score 
mGFP 
Coverage 
mGFP 
# 
PSM 
mGFP 
# 
Peptides 
mGFP 
Score 
mGFP-
WDR34 
Coverage 
mGFP-
WDR34 
# PSM 
mGFP-
WDR34 
# Peptides  
mGFP-
WDR34 Annotation 
G5E9H4 1139 126.7 Dynactin 1 (P150, 
glued homolog, 
Drosophila), 
isoform CRA_a 
OS=Homo sapiens 
GN=DCTN1  
2.70  1.14 1 1 10.04  1.05 1 1 
DYNACTIN 
H0YIC1 228 25.4 Bicaudal D-related 
protein 1 
(Fragment) 
OS=Homo sapiens 
GN=CCDC64  
n.d.  n.d.  n.d.  n.d.  2.43  4.39 1 1 
BICAUDAL D1 
B4DWL0 270 30.9 Bicaudal D-related 
protein 1 
OS=Homo sapiens 
GN=CCDC64  
19.73  5.19 2 1 n.d.   n.d. n.d.  n.d.  
BICAUDAL D 
RELATED 
PROTEIN 1 
I3L2U8 345 38.9 Platelet-activating 
factor 
acetylhydrolase IB 
subunit alpha 
OS=Homo sapiens 
GN=PAFAH1B1  
6.44  9.28 2 2 n.d.   n.d. n.d.  n.d.  
LIS1 
n.d. =  not detected 
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